Screener
Trevi Therapeutics, Inc. TRVI Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:09 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-206390
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss | $(13,192) | $(10,340) |
| Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted | 145,592,901 | 117,610,750 |
| Basic and diluted net loss per common share outstanding | $(0.09) | $(0.09) |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is Trevi Therapeutics, Inc.'s shares (diluted)?
- Trevi Therapeutics, Inc. (TRVI) reported shares (diluted) of 145.6M in Q1 2026.
- How has Trevi Therapeutics, Inc.'s shares (diluted) changed year-over-year?
- Trevi Therapeutics, Inc.'s shares (diluted) increased by 23.8% year-over-year, from 117.6M to 145.6M.
- What is the long-term trend for Trevi Therapeutics, Inc.'s shares (diluted)?
- Over 4 years (2021 to 2025), Trevi Therapeutics, Inc.'s shares (diluted) has grown at a 58.3% compound annual growth rate (CAGR), from 84M to 527.8M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Trevi Therapeutics, Inc.'s shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude